ClinicalTrials.gg
CompletedNCT02094469STELLA_ExtUpdated Jan 29, 2016

Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina

A Phase 3 interventional study of Cilostazol in Vasospastic Angina, sponsored by Korea Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-01-29.

Sponsored by Korea Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Angina Pectoris, Variant with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Angina Pectoris, Variant · Korea, Republic of.

Enrollment
7th of 10
65 · median 118
Started
2013
with 2 others
Phase 3
2 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
3 of 11
Korea Otsuka Pharmaceutical Co., Ltd.

Among the 11 studies in Angina Pectoris, Variant with a site in Korea, Republic of, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2013, is one of 2 in phase 3, and was the 6th registered.

Angina Pectoris, Variant

34 studies on the registry are indexed under Angina Pectoris, Variant; 10 are open to participants now.

Browse Angina Pectoris, Variant studies →

Open to participants now

2 of the 11 studies in Angina Pectoris, Variant with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 9 Angina Pectoris, Variant studies recruiting now, 8 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Angina Pectoris, Variant with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study will be conducted in accordance with the local regulation of New Drug Application. Overall duration of this trial will be 3 years after approval of MFDS.

Each subject will participate around 26 weeks, which include the 24 weeks treatment period and 2 weeks safety follow up period. Withdrawn subjects due to efficacy after 4 weeks treatment will participate in 6 weeks in total including 2 weeks safety follow up. Withdrawn subjects with other reason also have 2 weeks follow up period.

Read the detailed description

A Multicenter, One group, Open-label Study. Cilostazol will be treated for additional 24 weeks to the subject who had completed 021-KOA-1301i study. PletaalÒ(Cilostazol) is taken 100mg oral tablets bid during 2 3weeks after dosing of PletaalÒ(Cilostazol) 50mg oral tablets bid during 1 week. The dose can be adjusted by investigator's discretion during the study and the detailed method is described in the Protocol. Subject who has 2 or more chest pain at 4th week will be withdrawn from the study (But, subjects who show 50% or more of chest pain decrease compared to 1st week would not be withdrawn.). Subjects who participated in this trial will have 2 weeks follow-up after study completion.

03

Conditions studied

  • Vasospastic Angina

Keywords

  • Treatment for vasospastic angina
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 20 to 80 years, and subjects whose age at the time of enrollment was 80 in 021-KOA-1301i clinical trial and is 81 in this clinical trial
  2. Subjects who completed 021-KOA-1301i clinical trial
  3. Women of with negative pregnancy test at enrollment and who agree to practice a measure throughout the clinical trial (e.g., hormonal contraceptives, intrauterine devices, condom + spermicidal agents, diaphragm + spermicidal agents, and partner's infertility)
  4. Subjects who signed a written agreement indicating that they were given full explanations of the clinical trial and are willing to participate in the clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Subjects who fell under one of the exclusion criteria at the time of enrollment for 021-KOA-1301i
  2. Subjects who reported any of the following events, which fall under the exclusion criteria for KOA-1301i, between the initiation of 021-KOA-1301i participation and enrollment visit for 021-KOA-1302i

    • Myocardial infarction or myocardial infarction induced by vasospastic angina
    • Life-threatening vasospastic episodes (e.g., ventricular tachycardia, ventricular fibrillation, or syncope)
    • Stroke, intracranial hemorrhage, or (TIA)
    • Hemorrhage (hemophilia, capillary fragility, intracranial hemorrhage, upper gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.)
  3. Subjects who are currently using any of the medications in 021-KOA-1301i (excluding the product of 021-KOA-1301i) at baseline
  4. Subjects who meet the following criteria for baseline laboratory findings

    • severe anemia with ≤6.5 g/dl at baseline
    • Creatinine level ≥ 1.5 mg/dL at baseline
    • or ALT >3x at baseline
    • count \< 100,000mm3 at baseline
  5. Pulse rate exceeding 100 bpm when measured for vital signs at baseline: Tachycardia
  6. Hypotension with systolic pressure \< 90mmHg at baseline
  7. Uncontrolled hypertension defined as systolic pressure ≥ 160 mmHg or diastolic pressure ≥ 100 mmHg at baseline
  8. defined as QTcB > 450 msec for men and QTcB > 470 msec for women at baseline
  9. Women of with positive pregnancy test at baseline
  10. Women who do not agree to practice a measure, or are pregnant or lactating
  11. Subjects who are not expected to have the potential to benefit from additional administration of Cilostazol, according to the investigator's judgment
  12. Subjects otherwise judged by the investigator to be inappropriate for inclusion in the trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Other
    Cilostazol

    Cilostazol 50mg and 100mg

    Drug: Cilostazol

Interventions

  • Oral, Bid, 24 weeks

    Also known as: Pletaal

06

What researchers measure

Primary outcomes

  1. Proportion of the subjects whose chest pain was not present in the final 1 week/2 weeks after the 24-week treatment period

    Proportion of the subjects whose chest pain was not present in the final 1 week/2 weeks after the 24-week treatment period

    Time frame: 24 weeks

Secondary outcomes

  1. secondary 1

    Change/rate of change in the frequency of chest pain in the final 1week/2 weeks after the 24-week treatment period compared to those in the final 1 week/2weeks of Amlodipine run-in period in 021-KOA-1301i

    Time frame: 24 week

  2. secondary 2

    Mean change in the intensity of chest pain in the final 1 week/2 weeks after the 24-week treatment period compared to that in the final 1 week/2weeks of Amlodipine run-in period in 021-KOA-1301i

    Time frame: 4 weeks

  3. secondary 3

    4-week cumulative rate of subjects withdrawn due to lack of efficacy

    Time frame: 4 weeks

07

Study locations

1 site
  • Yangsan Busan University Hospital
    Busan, 626-770, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2014
First posted
Mar 21, 2014
Start
Dec 2013
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Last update
Jan 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02094469
Responsible party
Sponsor
First posted
Mar 21, 2014
Start date
Dec 2013
Primary completion
Jan 2016
Completion
Jan 2016
Last update
Jan 29, 2016

Study contacts

Junghong Kim, MD
principal investigator · Yangsan Busan University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion